After a long and winding road, Xbrane has now received FDA approval for Lucamzi, a biosimilar to the eye drug Lucentis.

A new drug combination extended survival by more than eight months in patients with extensive-stage small cell lung cancer, ...

AstraZeneca’s Enhertu is moving into earlier-stage breast cancer treatment after winning EU approval. In a phase III trial, ...

Following a sharp decline in sales, Swedish medtech company Miris is planning a SEK 20 million rights issue. At the same time ...

A new prostate cancer pill achieved a tumour response in 75 per cent of patients whose tumours could be measured in a phase I ...

Roche’s investigational cancer drug divarasib reduced the risk of death by 44 per cent compared with existing treatments in a phase III trial involving patients with lung cancer.

New treatments for ALS are raising hopes among researchers. “The earlier a patient receives targeted gene therapy, the ...

In May, Vitrolife announced that Bronwyn Brophy O'Connor had decided to step down as President and CEO to take up the same ...

Medical device manufacturers will be spared duplicate certification processes to access the British market. The UK government ...

MEMBER ANNOUNCEMENT - Gruber A/S will join the Danish Pavilion at COMPAMED in Düsseldorf on 16–19 November 2026, with a focus ...

AstraZeneca’s experimental cancer treatment sone-ve delivered longer survival than analysts had expected in a phase III trial ...

Eli Lilly’s advertising campaign about obesity did not breach industry rules on advertising aimed at the general public, ...